<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-29830</identifier>
<setSpec>0304-4815</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Response to the letter of M. C. Ahumada et al, on the article "Pharmacoeconomic analysis of methotrexate-resistant rheumatoid arthritis with combinations of leflunomide-methotrexate or infliximab-methotrexate"</dc:title>
<dc:creator>Romero, F. I</dc:creator>
<dc:creator>Domínguez-Gil Hurlé, A</dc:creator>
<dc:creator>Rubio-Terrés, C</dc:creator>
<dc:creator>Burell, A</dc:creator>
<dc:language>es</dc:language>
<dc:publisher>Ediciones Doyma, S.L.</dc:publisher>
<dc:description xml:lang="es">No disponible</dc:description>
<dc:source>Rev. esp. reumatol. (Ed. impr.);31(2): 100-102, feb. 2004.</dc:source>
<dc:identifier>ibc-29830</dc:identifier>
<dc:title xml:lang="es">Respuesta de los autores a la carta de Ahumada et al sobre el artículo "Análisis farmacoeconómico del tratamiento de la artritis reumatoide resistente a metotrexato con las combinaciones de leflunomida-metotrexato o infliximab-metotrexato"</dc:title>
<dc:subject>^d29638</dc:subject>
<dc:subject>^d28169^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d1178^s22057</dc:subject>
<dc:subject>^d22164</dc:subject>
<dc:type>article</dc:type>
<dc:date>200402</dc:date>
</metadata>
</record>
</ibecs-document>
